Platform / Overview A New Direction for Gene Therapy DeliverySTRM MVs represent a novel, biologically derived delivery modality for advanced genetic therapies. As naturally occurring nanoparticles, MVs can be engineered to carry gene editing tools, RNA payloads, or therapeutic DNA, while minimizing some of the safety concerns associated with traditional viral vectors or synthetic delivery […]
The privacy policy describes the information collected on the Sites, its use and disclosure, and applies to STRM.BIO’s website, mobile sites, and use of social media sites.
The STRM.BIO newsroom lists an $8 million Series Seed 2 financing announced on 7 Jan 2026 and an ARPA-H contract announced on 3 Dec 2025, both related to its gene delivery platform.
STRM.BIO is developing a non-viral delivery platform that uses STRM MVs to target bone marrow for in vivo delivery of therapeutics. Its initial focus is rare hematological diseases, with programs in Fanconi anemia and in vivo CAR-T therapies.
The page says delivery limits have constrained the promise of in vivo gene therapy and that STRM.BIO enables therapies designed around disease biology rather than delivery tradeoffs.
